



Published in final edited form as:

JAMA. 2009 September 9; 302(10): 1084–1091. doi:10.1001/jama.2009.1308.

## Evaluating Dopamine Reward Pathway in ADHD:

### Clinical Implications

**Dr. Nora D. Volkow, MD, Dr. Gene-Jack Wang, MD, Dr. Scott H. Kollins, PhD, Dr. Tim L. Wigal, PhD, Dr. Jeffrey H. Newcorn, MD, Dr. Frank Telang, MD, Dr. Joanna S. Fowler, PhD, Dr. Wei Zhu, PhD, Dr. Jean Logan, PhD, Dr. Yeming Ma, PhD, Dr. Kith Pradhan, MS, Dr. Christopher Wong, MS, and Dr. James M. Swanson, PhD**

National Institute on Drug Abuse (Dr Volkow) and Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism (Drs Volkow, Telang, and Ma), Bethesda, Maryland; Medical and Chemistry Departments, Brookhaven National Laboratory, Upton, New York (Drs Wang, Fowler, and Logan, Messrs Pradhan and Wong); Department of Psychiatry, Mount Sinai Medical Center, New York, New York (Drs Wang, Newcorn, and Fowler); Department of Psychiatry, Duke University Medical Center, Durham, North Carolina (Dr Kollins); Child Development Center, University of California, Irvine (Drs Wigal and Swanson); Department of Applied Mathematics and Statistics, State University of New York at Stony Brook, Stony Brook (Dr Zhu)

### Abstract

**Context**—Attention-deficit/hyperactivity disorder (ADHD)—characterized by symptoms of inattention and hyperactivity-impulsivity—is the most prevalent childhood psychiatric disorder that

---

Corresponding Author: Nora D. Volkow, MD, National Institute on Drug Abuse, 6001 Executive Blvd, Room 5274, MSC 9581, Bethesda, MD 20892 (nvolkow@nida.nih.gov).

**Author Contributions:** Dr Volkow had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

*Study concept and design:* Volkow, Wang, Wigal, Newcorn, Swanson.

*Acquisition of data:* Wang, Kollins, Wigal, Newcorn, Telang, Fowler, Pradhan.

*Analysis and interpretation of data:* Volkow, Wang, Kollins, Wigal, Newcorn, Zhu, Logan, Ma, Wong, Swanson.

*Drafting of the manuscript:* Volkow, Wang, Fowler.

*Critical revision of the manuscript for important intellectual content:* Volkow, Wang, Kollins, Wigal, Newcorn, Telang, Zhu, Logan, Ma, Pradhan, Wong, Swanson.

*Statistical analysis:* Zhu, Wong, Swanson.

*Obtained funding:* Volkow, Wang, Newcorn.

*Administrative, technical, or material support:* Wang, Kollins, Wigal, Telang, Fowler, Ma, Swanson.

*Study supervision:* Wang, Kollins, Wigal, Fowler.

**Financial Disclosures:** Dr Kollins reported receiving research support, consulting fees, or both from the following sources: Adrenex Pharmaceuticals, Otsuka Pharmaceuticals, Shire Pharmaceuticals, NIDA, NIMH, NINDS, NIEHS, EPA. Dr Newcorn reported being a recipient of research support from Eli Lilly and Ortho-McNeil Janssen, serves as a consultant, advisor, or both for Astra Zeneca, BioBehavioral Diagnostics, Eli Lilly, Novartis, Ortho-McNeil Janssen, and Shire and as a speaker for Ortho-McNeil Janssen. Dr Swanson reported receiving support from Alza, Richwood, Shire, Celgene, Novartis, Celltech, Gliatech, Cephalon, Watson, CIBA, Janssen, and McNeil; has been on advisory boards of Alza, Richwood, Shire, Celgene, Novartis, Celltech, UCB, Gliatech, Cephalon, McNeil, and Eli Lilly; has been on the speakers bureaus of Alza, Shire, Novartis, Celltech, UCB, Cephalon, CIBA, Janssen, and McNeil; and has consulted to Alza, Richwood, Shire, Celgene, Novartis, Celltech, UCB, Gliatech, Cephalon, Watson, CIBA, Janssen, McNeil and Eli Lilly. Dr Wigal reported receiving support from Eli Lilly, McNeil, Novartis, and Shire. No other financial disclosures were reported.

**Additional information:** The eTable is available at <http://www.jama.com>.

**Additional Contributions:** We thank the following BNL employees: Donald Warner for PET operations; David Schlyer and Michael Schueller for cyclotron operations; Pauline Carter, Millard Jayne, and Barbara Hubbard for nursing care; Payton King for plasma analysis; and Lisa Muench, Youwen Xu, and Colleen Shea for radiotracer preparation; and Karen Appelskog-Torres for protocol coordination. We also thank Duke employees Joseph English and Allan Chrisman for participant recruitment and evaluation; and NIH employee Linda Thomas for editorial assistance. We also thank the individuals who volunteered for these studies. None of the authors or the individuals acknowledged was compensated for their contributions other than their salaries.

frequently persists into adulthood, and there is increasing evidence of reward-motivation deficits in this disorder.

**Objective**—To evaluate biological bases that might underlie a reward/motivation deficit by imaging key components of the brain dopamine reward pathway (mesoaccumbens).

**Design, Setting, and Participants**—We used positron emission tomography to measure dopamine synaptic markers (transporters and D<sub>2</sub>/D<sub>3</sub> receptors) in 53 nonmedicated adults with ADHD and 44 healthy controls between 2001–2009 at Brookhaven National Laboratory.

**Main Outcome Measures**—We measured specific binding of positron emission tomographic radioligands for dopamine transporters (DAT) using [<sup>11</sup>C]cocaine and for D<sub>2</sub>/D<sub>3</sub> receptors using [<sup>11</sup>C]raclopride, quantified as binding potential (distribution volume ratio –1).

**Results**—For both ligands, statistical parametric mapping showed that specific binding was lower in ADHD than in controls (threshold for significance set at  $P < .005$ ) in regions of the dopamine reward pathway in the left side of the brain. Region-of-interest analyses corroborated these findings. The mean (95% confidence interval [CI] of mean difference) for DAT in the nucleus accumbens for controls was 0.71 vs 0.63 for those with ADHD (95% CI, 0.03–0.13,  $P = .004$ ) and in the midbrain for controls was 0.16 vs 0.09 for those with ADHD (95% CI, 0.03–0.12;  $P \leq .001$ ); for D<sub>2</sub>/D<sub>3</sub> receptors, the mean accumbens for controls was 2.85 vs 2.68 for those with ADHD (95% CI, 0.06–0.30,  $P = .004$ ); and in the midbrain, it was for controls 0.28 vs 0.18 for those with ADHD (95% CI, 0.02–0.17,  $P = .01$ ). The analysis also corroborated differences in the left caudate: the mean DAT for controls was 0.66 vs 0.53 for those with ADHD (95% CI, 0.04–0.22;  $P = .003$ ) and the mean D<sub>2</sub>/D<sub>3</sub> for controls was 2.80 vs 2.47 for those with ADHD (95% CI, 0.10–0.56;  $P = .005$ ) and differences in D<sub>2</sub>/D<sub>3</sub> in the hypothalamic region, with controls having a mean of 0.12 vs 0.05 for those with ADHD (95% CI, 0.02–0.12;  $P = .004$ ). Ratings of attention correlated with D<sub>2</sub>/D<sub>3</sub> in the accumbens ( $r = 0.35$ ; 95% CI, 0.15–0.52;  $P = .001$ ), midbrain ( $r = 0.35$ ; 95% CI, 0.14–0.52;  $P = .001$ ), caudate ( $r = 0.32$ ; 95% CI, 0.11–0.50;  $P = .003$ ), and hypothalamic ( $r = 0.31$ ; CI, 0.10–0.49;  $P = .003$ ) regions and with DAT in the midbrain ( $r = 0.37$ ; 95% CI, 0.16–0.53;  $P \leq .001$ ).

**Conclusion**—A reduction in dopamine synaptic markers associated with symptoms of inattention was shown in the dopamine reward pathway of participants with ADHD.

Attention-deficit/hyperactivity disorder (ADHD) is characterized by symptoms of inattention, hyperactivity, or impulsivity that produce impairment across cognitive, behavioral, and interpersonal domains.<sup>1</sup> Although for many years it was believed to be a disorder of childhood and adolescence, it is now recognized to also occur in adulthood. It is estimated that ADHD affects 3% to 5% of the US adult population,<sup>2</sup> which makes it one of the most prevalent of all psychiatric disorders.

Genetic and environmental etiologies that implicate the neurotransmitter dopamine have been proposed for ADHD.<sup>3</sup> Genetic studies have identified a few genes with polymorphisms associated with ADHD, with the most replicated being 2 dopamine genes (eg, *DRD4* and *DAT 1* genes),<sup>3</sup> and environmental studies have identified important non-genetic risk factors (eg, maternal smoking during pregnancy and lead levels) that also may affect the dopamine systems of the brain.<sup>4</sup> Evidence from brain imaging studies have shown that brain dopamine neurotransmission is disrupted in ADHD<sup>5–9</sup> and that these deficits may underlie core symptoms of inattention<sup>8</sup> and impulsivity.<sup>9</sup>

There is also increased awareness that patients with ADHD may have reward and motivation deficits.<sup>10–12</sup> Although defined in different way across studies, this reward-motivation deficit is typically characterized by abnormal behavior change following conditions of reward and punishment. For example, compared with nondiagnosed children, those with ADHD do not modify their behavior in the face of changing reward conditions.<sup>13</sup> The mesoaccumbens dopamine pathway, which projects from the ventral tegmental area (VTA) in the midbrain to

the nucleus accumbens is critically involved in reward and motivation<sup>14</sup> and has been hypothesized to underlie the reward and motivational deficits observed in ADHD.<sup>11,15</sup> Indeed recent functional magnetic resonance imaging (fMRI) studies showed decreased nucleus accumbens activation with processing of reward in participants with ADHD.<sup>16,17</sup> However, to our knowledge no study has directly measured synaptic dopamine markers in the accumbens region of individuals with ADHD.

Based on this, we hypothesized abnormalities in the mesoaccumbens dopamine pathway (composed of dopamine cells in the midbrain and their projections to the accumbens) in ADHD. To test this hypothesis, we evaluated dopamine D<sub>2</sub>/D<sub>3</sub> receptor(dopamine postsynaptic marker) and DAT(dopamine presynaptic marker) availability in these brain regions in 53 adult participants with ADHD (never medicated) and 44 non-ADHD controls using positron emission tomography (PET) and both [<sup>11</sup>C]raclopride and [<sup>11</sup>C]cocaine (D<sub>2</sub>/D<sub>3</sub> receptor and DAT radioligands respectively).<sup>18,19</sup>

## METHODS

### Participants

The PET imaging was carried out at Brookhaven National Laboratory and patient recruitment and evaluation occurred at Duke University, Mount Sinai Medical Center, and University of California, Irvine, from 2001–2009. Institutional review board approval was obtained from all participating institutions. Written informed consent was obtained from all participants after the study had been fully explained to them. Participants were paid for their participation. We studied 53 never-medicated ADHD patients (including 20 described in a prior report of striatal DAT and dopamine release<sup>6,8</sup>) and 44 healthy controls. Participants with ADHD were recruited from clinical referrals to the ADHD programs at each institution.

To minimize confounding from prior drug exposures or comorbidity, participants were excluded if they had a prior history of substance abuse (other than nicotine) or with positive urine drug screen results, prior or current treatment with psychotropic medications (including stimulants), psychiatric comorbidities (axis I or II diagnosis other than ADHD), neurological disease, medical conditions that may alter cerebral function (ie, cardiovascular, endocrinological, oncological, or autoimmune diseases), or head trauma with loss of consciousness (>30 minutes). These rigorous exclusion criteria contributed to the length of the study (from 2001 to 2009).

Two clinicians interviewed the patients to ensure that *Diagnostic and Statistical Manual of Mental Disorders*(Fourth Edition) (*DSM-IV*) diagnostic criteria were met, including the presence of at least 6 of 9 inattention symptoms (with or without 6 of 9 hyperactive or impulsive symptoms) as ascertained with a semi-structured psychiatric interview using modifications for adult prompts of ADHD behaviors. The Clinical Global Impressions Severity scale<sup>20</sup> was used to assess overall impairment. For diagnosis, ADHD participants were required to have at least a moderate severity level of 4 or greater. In addition, evidence was required from each participant's history that some symptoms of ADHD started before age 7 years. Controls were recruited from advertisements in the local newspapers and met the same exclusion criteria but not the inclusion criteria for diagnosis of ADHD. Controls were excluded if they described symptoms of inattention or hyperactivity that interfered with everyday activities. Table 1 provides demographic and clinical characteristics of the participants.

### Clinical Scales

The *DSM-IV* ADHD items were assessed using the Strengths and Weaknesses of ADHD-symptoms and Normal-behavior (SWAN) rating scale, which uses a positive scale for

symptoms (1 to 3) and a negative scale for the opposite of the symptoms (-1 to -3) ranging from far below average to far above average.<sup>21</sup> This allows one to assess the full range of functioning in the 2 domains of ADHD defined as dimensions in the population (ie, attention and activity or reflectivity) to be assessed rather than the severity of psychopathology related to presence of inattention and hyperactivity-impulsivity symptoms in those with ADHD. The range for the scores of the SWAN is -3 to 3. The psychometric properties of the SWAN rating scale are superior to those of truncated symptom-severity ratings scales.<sup>22</sup> Ratings on the SWAN were completed on 46 ADHD participants and 38 controls and were used to assess the correlations between these dimensions across all participants and the PET dopamine measures (Table 1).

Also obtained was the Conners Adult ADHD Rating Scale long version, which provides self-assessment of severity of ADHD symptoms on a 4-point scale (not at all, 0; just a little, 1; pretty much, 2; and very much, 3). Eight scores are provided (range of possible scores): A, inattention/memory problems (0–36); B, hyperactivity/restlessness (0–36); C, impulsivity/emotional lability (0–36); D, problems with self-concept (0–18); E, *DSM-IV* inattentive symptoms (0–27); F, *DSM-IV* hyperactive-impulsive symptoms (0–27); G, *DSM-IV* symptom total (0–54); and H, ADHD index (0–36).<sup>23</sup> This rating system has been widely used in clinical and research settings and has well-established factor structure, reliability, and validity (Table 1).<sup>24</sup>

## PET Scans

A Siemens HR<sup>+</sup> tomograph was used (Siemens/CTIKnoxville, Tennessee; resolution 4.5 × 4.5 × 4.5 mm full width half-maximum). Dynamic scans were started immediately after injection of 4 to 10 mCi of [<sup>11</sup>C]raclopride (specific activity 0.5–1.5 Ci/μM at end of bombardment) and after injection of 4 to 8 mCi of [<sup>11</sup>C]cocaine (specific activity >0.53 Ci/μmol at end of bombardment) and were obtained for a total of 60 minutes as previously described.<sup>18,19</sup> Arterial blood was obtained to measure the concentration of unchanged [<sup>11</sup>C]raclopride<sup>18</sup> and [<sup>11</sup>C]cocaine<sup>19</sup> in plasma. For this study, [<sup>11</sup>C]cocaine was chosen as the DAT radioligand because its specific binding is selective for DAT (its binding is inhibited by drugs that block the DAT but not by drugs that block the norepinephrine or the serotonin transporters)<sup>25</sup>; it provides with reproducible measures when participants are tested on separate occasions<sup>19</sup> and its kinetics are ideal for in vivo quantification.<sup>26</sup> Moreover, its synthesis is very reliable, which is important when conducting complex multitracer studies like those performed in this study.

## Image Analysis and Statistics

The [<sup>11</sup>C]raclopride and the [<sup>11</sup>C]cocaine images were transformed into distribution volume ratio images by computing the total distribution volume in each pixel and then dividing it by the distribution volume in the cerebellum. To obtain the distribution volume, circular regions in the cerebellar hemispheres were extracted in 2 planes located at -28 mm and -36 mm from the intercommissural plane. The cerebellar regions were then projected to the dynamic scans to obtain concentrations of <sup>11</sup>C vs time, which along with the concentration of unchanged tracer in plasma were used to calculate the distribution volume in the cerebellum, using a graphical analysis technique for reversible systems.<sup>26</sup>  $B_{\max}/K_d$  (distribution volume ratio -1, for which  $K_d$  and  $B_{\max}$  are the effective in vivo constants in the presence of endogenous neurotransmitter and nonspecific binding) was used as the measure of D<sub>2</sub>/D<sub>3</sub> receptor and DAT availability.<sup>26</sup> The ratio  $B_{\max}/K_d$  measured in this way is referred to as the binding potential, BP<sub>ND</sub>. Also measured was the plasma-to-tissue transfer constant ( $K_1$ ) in striatum and cerebellum for both radioligands using the graphical analysis technique.<sup>26</sup>

Statistical parametric mapping<sup>27</sup> was used to assess the differences in the distribution volume ratio images (for both [<sup>11</sup>C]raclopride and [<sup>11</sup>C]cocaine images) between controls and

participants with ADHD without an a priori selection of anatomical brain regions. For this purpose the distribution volume ratio images were spatially normalized using the Montreal Neurological Institute template provided in the statistical parametric mapping 99 package (Wellcome Trust Centre for Neuroimaging, London, England) and subsequently smoothed with a 16-mm isotropic Gaussian kernel. Independent samples *t* tests were performed to compare the differences between groups. Significance was set at  $P < .005$  (cluster corrected  $> 100$  voxels) and statistical maps were overlaid on an MRI structural image.

Significance detected by statistical parametric mapping was corroborated with independently drawn region-of-interest analyses using templates from the Talairach Daemon database.<sup>28</sup> Figure 1 shows the location of the region of interest used for this analysis. Differences in D<sub>2</sub>/D<sub>3</sub> receptor and DAT availability were assessed with independent samples *t* tests (2 tailed).

Pearson product-moment correlations were used to assess the relationship between the DAT and D<sub>2</sub>/D<sub>3</sub> receptors and the 2 dimensions of the SWAN rating score (attention and activity or reflectivity).

Definitions for significant difference for the outcome measures<sup>1</sup> were that statistical parametric mapping comparisons for the DAT and the D<sub>2</sub>/D<sub>3</sub> images had to be significant at  $P < .005$  (cluster corrected  $> 100$  voxels) and the regional findings had to be corroborated by independently drawn region of interests<sup>2</sup>; comparisons for these corroborative measures had to be significant at  $P < .05$ <sup>3</sup>; correlations analyses had to be significant at  $P < .006$ , which was chosen to maintain an overall significance level of  $P < .05$  based on a Bonferroni correction for 4 regions and 2 clinical measures (attention and activity or reflectivity). The statistical package used was Statview, version 5.0.1 (Abacus Concepts, Berkeley, California).

Sample-size calculation for this study was based on our preliminary studies (with smaller sample sizes) on DAT<sup>6</sup> and D<sub>2</sub>/D<sub>3</sub> receptors,<sup>8</sup> which revealed a difference in caudate between groups at an effect size (ratio between the mean difference and the pooled standard deviation) between 0.65 and 0.80. For such effect sizes, to achieve a power of at least 80% using the independent samples *t* test with a significance level of .05 (2 sided), we needed to recruit at least 40 participants per group. The eventual sample sizes of 53 in the ADHD and 44 in the control groups allowed the detection of the estimated mean differences with a power between 88% and 97% via the independent samples *t* test at the significance level of .05 (2 sided).

## RESULTS

### Dopamine D<sub>2</sub>/D<sub>3</sub> Receptors

Statistical parametric mapping analysis of the [<sup>11</sup>C]raclopride distribution volume ratio images revealed 1 cluster with lower D<sub>2</sub>/D<sub>3</sub> availability in ADHD participants than controls in the left hemisphere. This cluster included brain regions of the dopamine reward pathway—ventral caudate, accumbens, and midbrain regions, as well as the hypothalamic region (Figure 2 and the eTable available at <http://www.jama.com>). These findings were confirmed by independently drawn region of interest, which also showed ADHD-control differences in left accumbens, midbrain, caudate, and in hypothalamic regions (Table 2). There were no regions that were higher in ADHD participants than in controls. In contrast the K<sub>1</sub> measures for [<sup>11</sup>C]raclopride (transport of radioligand from plasma to tissue) did not differ either in left caudate with the both groups having a mean 0.11 (95% confidence interval [CI],  $-0.01$  to  $0.006$  mean difference) or in left accumbens region with the controls having a mean of 0.12 vs a mean of 0.11 for those with ADHD (95% CI,  $-0.01$  to  $0.005$ ).

## Dopamine Transporters

Statistical parametric mapping analysis of the [<sup>11</sup>C]cocaine distribution volume ratio images revealed a cluster in the same location as manifested in the [<sup>11</sup>C]raclopride images. This cluster included the left ventral caudate, accumbal, midbrain, and hypothalamic regions, and in these regions the mean DAT availability was lower in ADHD participants than controls (Figure 2 and eTable). There were no regions that were higher in ADHD participants than in controls. Independently drawn region of interest corroborated significantly lower DAT availability in left accumbens, midbrain, and caudate among participants with ADHD than among controls, but the reductions in left hypothalamic region were not significantly different (Table 2). The mean (95% CI for mean difference) of the K<sub>1</sub> measures for [<sup>11</sup>C]cocaine did not differ in the left caudate with 0.49 among the controls vs 0.48 among those with ADHD (95% CI, -0.05 to 0.03) or in left accumbens region with a respective difference of 0.49 vs 0.51 among those with ADHD (95% CI, -0.02 to 0.07).

## Correlation With ADHD Symptoms Dimensions

The dimension of attention (from the SWAN) was negatively correlated with D<sub>2</sub>/D<sub>3</sub> receptor availability in the left accumbens region ( $r=0.35$ ; 95% CI, 0.15–0.52;  $P=.001$ ), left midbrain ( $r = 0.35$ ; 95% CI, 0.14–0.52;  $P = .001$ ), left caudate ( $r = 0.32$ ; 95% CI, 0.11–0.50;  $P=.003$ ), and left hypothalamic region ( $r=0.31$ ; 95% CI, 0.10–0.49;  $P=.003$ ) and with DAT availability in left midbrain ( $r=0.37$ ; CI, 0.16, 0.53;  $P<.001$ ; Figure 3). Because the SWAN scale rates symptoms with a positive scale (from 1 to 3) and the opposite of symptoms with a negative scales (from -1 to -3) the negative correlation indicates that the lower the dopamine measures, the greater the symptoms of inattention. None of the correlations with the dimension of activity or reflectivity was significant.

## COMMENT

This study provides evidence in favor of the predicted disruption in the mesoaccumbens dopamine pathway in ADHD. With PET imaging, lower D<sub>2</sub>/D<sub>3</sub> receptor and DAT availability in those with ADHD than in the control group was documented in 2 key brain regions for reward and motivation (accumbens and midbrain).<sup>29</sup> It also corroborates disruption of synaptic dopamine markers in caudate in adults with ADHD and provides preliminary evidence that the hypothalamus may also be affected.

The lower than normal D<sub>2</sub>/D<sub>3</sub> receptor and DAT availability in the accumbens and midbrain regions supports the hypothesis of an impairment of the dopamine reward pathway in ADHD.<sup>30</sup> Because measures of reward sensitivity were not measured, we can only infer that the impairment in the dopamine reward pathway could underlie the clinical evidence of abnormal responses to reward in ADHD. The reward deficits in ADHD are characterized by a failure to delay gratification, impaired response to partial schedules of reinforcement, and preference for small immediate rewards over larger delayed rewards.<sup>31</sup> Consistent with this important clinical feature of the ADHD syndrome, a recent fMRI study reported decreased activation of the ventral striatum (wherein nucleus accumbens is located) for both immediate and delayed rewards in adult participants with ADHD compared with controls.<sup>17</sup>

In our study, the D<sub>2</sub>/D<sub>3</sub> receptor measures in accumbens were correlated with the dimension of attention, which would implicate the dopamine reward pathway in the symptoms of inattention in ADHD. This could provide an explanation of why the attentional deficits in individuals with ADHD are most evident in tasks that are considered boring, repetitive, and uninteresting (ie, tasks or assignments that are not intrinsically rewarding).<sup>32</sup> Finally, because a low number of dopamine D<sub>2</sub>/D<sub>3</sub> receptors in the nucleus accumbens have been associated with a greater risk for drug abuse,<sup>33</sup> future work should determine if the lower than normal

D<sub>2</sub>/D<sub>3</sub> receptor availability in the accumbens region in ADHD underlies the higher vulnerability for substance abuse in this population.<sup>34</sup>

The lower D<sub>2</sub>/D<sub>3</sub> receptor and DAT availability in the midbrain, which contains most of the dopamine neurons in the brain, is consistent with findings from prior imaging studies of children and adolescents with ADHD documenting midbrain abnormalities.<sup>5,35</sup> This could underlie the decreased dopamine release reported in adults with ADHD<sup>8</sup> because firing of dopamine neurons in the midbrain is responsible for release of dopamine in striatum. Moreover, the negative correlation between dopamine markers in the midbrain and the dimension of attention (DAT and D<sub>2</sub> receptors) suggests that impaired signaling from dopamine cells may contribute to severity of symptoms of inattention in ADHD.

Lower than normal D<sub>2</sub>/D<sub>3</sub> receptors and DAT availability in ADHD in the caudate was also demonstrated. Prior imaging studies had reported smaller caudate volumes<sup>36–40</sup> and caudate functional under activation<sup>41,42</sup> in ADHD participants compared with controls. In contrast, DAT findings in striatum (including caudate) have been inconsistent in studies of participants with ADHD vs controls, with some studies reporting high,<sup>43</sup> others low,<sup>6</sup> and others no differences.<sup>44</sup> Reason(s) for the discrepancies have been outlined elsewhere<sup>6</sup> and could reflect differences in radiotracers, the methods used (radiotracers; PET vs single photon emission computed tomography), differences in patients characteristics (including prior medication histories; comorbidities, and age of participants), and sample sizes, which vary from 6 to 53 (in this study). These findings differ from those reported in adolescents with ADHD, which showed higher D<sub>2</sub>/D<sub>3</sub> receptor availability in the left striatum (including caudate) than in young adults, that was interpreted to reflect deficient dopamine occupancy of these receptors.<sup>7</sup> In these adolescents with ADHD, the largest increases in striatal D<sub>2</sub>/D<sub>3</sub> receptor availability were seen in those patients who at birth had the lowest cerebral blood flow measures, which was interpreted to reflect the adverse consequences of neonatal distress on dopamine brain function.<sup>9</sup>

The preliminary finding reported herein of lower than normal dopamine D<sub>2</sub>/D<sub>3</sub> receptor availability in the hypothalamic region of ADHD participants is intriguing because if replicated, it could hypothetically provide a neurobiological basis for the high co-morbidity of ADHD with signs and symptoms suggestive of hypothalamic pathology<sup>45</sup> such as sleep disturbances,<sup>46</sup> overweight or obesity,<sup>47</sup> and abnormal responses to stress.<sup>48</sup> Multiple hypothalamic nuclei express dopamine D<sub>2</sub> receptors,<sup>49</sup> but the limited spatial resolution of a PET scan does not allow for localizing where the differences between the groups occurred. Relevant to the role of the hypothalamus in ADHD is the association of a mutation in the melanocortin-4-receptor (*MC4R*) gene, expressed in several hypothalamic nuclei that results in obesity, with ADHD.<sup>50</sup>

Our findings of an association of the mesoaccumbens dopamine pathway with ADHD inattention symptoms may have clinical relevance. This pathway plays a key role in reinforcement-motivation and in learning stimuli-reward associations,<sup>51</sup> and its involvement in ADHD supports the use of interventions to enhance the saliency of school and work tasks to improve performance. Both motivational interventions and contingency management have been shown to improve performance in ADHD patients.<sup>52</sup> Also stimulant medications have been shown to increase the saliency of a cognitive task (motivation, interest) in proportion to the drug-induced dopamine increases in striatum.<sup>53</sup>

## Limitations

[<sup>11</sup>C] Raclopride measures are influenced by extracellular dopamine (the higher the extracellular dopamine, the less the binding of [<sup>11</sup>C]raclopride to D<sub>2</sub>/D<sub>3</sub> receptors), and thus low-binding potential could reflect low D<sub>2</sub>/D<sub>3</sub> receptor levels or increased dopamine release.

<sup>54</sup> However, the latter is unlikely since we had previously reported that dopamine release in a sub-group of our ADHD participants was lower than in controls.<sup>8</sup> Also although [<sup>11</sup>C]cocaine's binding to DATs is minimally affected by competition with endogenous dopamine,<sup>55</sup> DAT availability reflects not only the density of dopamine terminals but also synaptic dopamine tone, because DAT up-regulates when synaptic dopamine is high and down-regulates when dopamine is low.<sup>56</sup> Thus low DAT availability could reflect fewer dopamine terminals or decreased DAT expression per dopamine terminal.

The relatively low affinity of [<sup>11</sup>C]raclopride and [<sup>11</sup>C]cocaine for their targets makes them better suited to measure regions with high D<sub>2</sub>/D<sub>3</sub> receptor or DAT density (ie, caudate, putamen, and accumbens) and less sensitive to regions with lower levels such as the hypothalamus and midbrain. However, despite this limitation, significant differences in the latter regions between controls and participants with ADHD was shown.

Another study limitation was that measures of reward sensitivity were not performed. Thus, we can only infer that the decreases in the dopamine markers in the accumbens region could underlie the reward deficits that have been reported in patients with ADHD.

Morphological MRI images were not obtained and thus whether volumetric differences in striatum in those with ADHD that could account for these findings could not be ascertained since volumetric differences in striatum have been reported in ADHD.<sup>36–40</sup> However, that there were no group differences in measures of K<sub>1</sub> (transport of radiotracer from plasma to tissue) in striatum, which would have also been affected by volumetric changes, indicates that these findings reflect decreased availability of DAT and D<sub>2</sub>/D<sub>3</sub> receptors rather than decreases secondary to partial volume effects.

The correlations with reflectivity or impulsivity and the PET dopamine measures were not significant, which could reflect that the scores were low and thus the sensitivity to observe such a correlation was lacking. Alternatively it could reflect the involvement of frontal regions in impulsivity,<sup>57</sup> which could not be measured with current PET radioligands; D<sub>2</sub>/D<sub>3</sub> receptors and DAT levels in frontal regions are very low.

Although the significant findings in this study are restricted to the left hemisphere, low statistical power may have contributed to the lack of significant ADHD-normal differences in the right brain regions. Moreover, because an a priori laterality hypothesis was lacking and, to our knowledge, no solid evidence exists in the literature to support laterality for reward, the laterality effects should be interpreted as preliminary and in need of replication.

This study was not initially designed to evaluate hypothalamic dopamine involvement in ADHD. Thus, this finding is preliminary and in need of replication. Moreover, future studies designed to evaluate hypothalamic pathology in ADHD and its potential clinical significance should assess sleep pathology and should not exclude obese participants, as was the case for the current study.

In conclusion, these findings show a reduction in dopamine synaptic markers in the dopamine reward pathway midbrain and accumbens region of participants with ADHD that were associated with measures of attention. It also provides preliminary evidence of hypothalamic involvement in ADHD (lower than normal D<sub>2</sub>/D<sub>3</sub> receptor availability).

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.



## Acknowledgments

**Funding/Support:** This research was carried out at Brookhaven National Laboratory (BNL) and was supported in part by grant MH66961-02 from the Intramural Research Program of the National Institutes of Health (NIH), the National Institute of Mental Health and infrastructure support from the Department of Energy.


**Role of the Sponsor:** The funding agencies did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

## References

1. National Institutes of Health Consensus Development Conference Statement. *J Am Acad Child Adolesc Psychiatry* 2000;39(2):182–193. [PubMed: 10673829]
2. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. *Pharmacotherapy* 2009;29(6):656–679. [PubMed: 19476419]
3. Swanson JM, Kinsbourne M, Nigg J, et al. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. *Neuropsychol Rev* 2007;17(1):39–59. [PubMed: 17318414]
4. Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP. Exposures to environmental toxicants and attention deficit hyperactivity disorder in US children. *Environ Health Perspect* 2006;114(12):1904–1909. [PubMed: 17185283]
5. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM. High midbrain [18F]DOPA accumulation in children with attention deficit hyper-activity disorder. *Am J Psychiatry* 1999;156(8):1209–1215. [PubMed: 10450262]
6. Volkow ND, Wang GJ, Newcorn J, et al. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. *Neuroimage* 2007;34(3):1182–1190. [PubMed: 17126039]
7. Lou HC, Rosa P, Pryds O, et al. ADHD: increased dopamine receptor availability linked to attention deficit and low neonatal cerebral blood flow. *Dev Med Child Neurol* 2004;46(3):179–183. [PubMed: 14995087]
8. Volkow ND, Wang GJ, Newcorn J, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry* 2007;64(8):932–940. [PubMed: 17679638]
9. Rosa Neto P, Lou H, Cumming P, Pryds O, Gjedde A. Methylphenidate-evoked potentiation of extracellular dopamine in the brain of adolescents with premature birth. *Ann N Y Acad Sci* 2002;965:434–439. [PubMed: 12105118]
10. Luman M, Oosterlaan J, Sergeant JA. The impact of reinforcement contingencies on AD/HD. *Clin Psychol Rev* 2005;25(2):183–213. [PubMed: 15642646]
11. Johansen EB, Killeen PR, Russell VA, et al. Origins of altered reinforcement effects in ADHD. *Behav Brain Funct* 2009;5:7. [PubMed: 19226460]
12. Haenlein M, Caul WF. Attention deficit disorder with hyperactivity. *J Am Acad Child Adolesc Psychiatry* 1987;26(3):356–362. [PubMed: 3597291]
13. Kollins SH, Lane SD, Shapiro SK. The experimental analysis of childhood psychopathology. *Psychol Rec* 1997;47(1):25–44.
14. Wise RA. Brain reward circuitry. *Neuron* 2002;36(2):229–240. [PubMed: 12383779]
15. Sonuga-Barke EJ. Causal models of attention-deficit/hyperactivity disorder. *Biol Psychiatry* 2005;57(11):1231–1238. [PubMed: 15949993]
16. Ströhle A, Stoy M, Wrase J, et al. Reward anticipation and outcomes in adult males with attention-deficit/hyperactivity disorder. *Neuroimage* 2008;39(3):966–972. [PubMed: 17996464]
17. Plichta MM, Vasic N, Wolf RC, et al. Neural hypo-responsiveness and hyper-responsiveness during immediate and delayed reward processing in adult attention-deficit/hyperactivity disorder. *Biol Psychiatry* 2009;65(1):7–14. [PubMed: 18718573]
18. Volkow ND, Fowler JS, Wang GJ, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. *J Nucl Med* 1993;34(4):609–613. [PubMed: 8455077]
19. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. *Synapse* 1989;4(4):371–377. [PubMed: 2557686]


20. Guy, W. Clinical Global Impression (CGI) scale. In: Rush, AJ.; First, MB.; Blacker, D., editors. *Handbook of Psychiatric Measures*. Washington, DC: American Psychiatric Publishing; 2000.
21. Swanson JM, Deutsch C, Cantwell D, et al. Genes and attention-deficit hyperactivity disorder. *Clin Neurosci Res* 2001;1:207–216.
22. Young DJ, Levy F, Martin NC, Hay DA. Attention deficit hyperactivity disorder: a Rasch analysis of the SWAN rating scale [published online May 20, 2009]. *Child Psychiatry Hum Dev*. 10.1007/s10578-009-0143-z
23. Conners CK. Rating scales in attention-deficit/hyperactivity disorder. *J Clin Psychiatry* 1998;59(suppl 7):24–30. [PubMed: 9680050]
24. Conners, CK.; Erhardt, D.; Sparrow, E. *Adult ADHD Rating Scales: Technical Manual*. North Tonawanda, NY: Multi-Health Systems Inc; 1999.
25. Volkow ND, Fowler JS, Logan J, et al. Carbon-11-cocaine binding compared at subpharmacological and pharmacological doses. *J Nucl Med* 1995;36(7):1289–1297. [PubMed: 7790958]
26. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. *J Cereb Blood Flow Metab* 1990;10(5):740–747. [PubMed: 2384545]
27. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging. *Hum Brain Mapp* 1995;2:189–210.
28. Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach atlas labels for functional brain mapping. *Hum Brain Mapp* 2000;10(3):120–131. [PubMed: 10912591]
29. Wise RA, Rompre PP. Brain dopamine and reward. *Annu Rev Psychol* 1989;40:191–225. [PubMed: 2648975]
30. Sonuga-Barke EJ. The dual pathway model of AD/HD. *Neurosci Biobehav Rev* 2003;27(7):593–604. [PubMed: 14624804]
31. Tripp G, Wickens JR. Dopamine transfer deficit. *J Child Psychol Psychiatry* 2008;49(7):691–704. [PubMed: 18081766]
32. Barkley, RA. *Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment*. New York, NY: The Guilford Press; 1990.
33. Dalley JW, Fryer TD, Brichard L, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. *Science* 2007;315(5816):1267–1270. [PubMed: 17332411]
34. Elkins IJ, McGue M, Iacono WG. Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. *Arch Gen Psychiatry* 2007;64(10):1145–1152. [PubMed: 17909126]
35. Jucaite A, Fernell E, Halldin C, Forsberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder. *Biol Psychiatry* 2005;57(3):229–238. [PubMed: 15691523]
36. Castellanos FX, Giedd JN, Marsh WL, et al. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. *Arch Gen Psychiatry* 1996;53(7):607–616. [PubMed: 8660127]
37. Filipek PA, Semrud-Clikeman M, Steingard RJ, Renshaw PF, Kennedy DN, Biederman J. Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. *Neurology* 1997;48(3):589–601. [PubMed: 9065532]
38. Castellanos FX, Giedd JN, Berquin PC, et al. Quantitative brain magnetic resonance imaging in girls with attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry* 2001;58(3):289–295. [PubMed: 11231836]
39. Lopez-Larson M, Michael ES, Terry JE, et al. Subcortical differences among youths with attention-deficit/hyperactivity disorder compared to those with bipolar disorder with and without attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2009;19(1):31–39. [PubMed: 19232021]
40. Qiu A, Crocetti D, Adler M, et al. Basal ganglia volume and shape in children with attention deficit hyperactivity disorder. *Am J Psychiatry* 2009;166(1):74–82. [PubMed: 19015232]
41. Vaidya CJ, Bunge SA, Dudukovic NM, Zalecki CA, Elliott GR, Gabrieli JD. Altered neural substrates of cognitive control in childhood ADHD. *Am J Psychiatry* 2005;162(9):1605–1613. [PubMed: 16135618]

42. Booth JR, Burman DD, Meyer JR, et al. Larger deficits in brain networks for response inhibition than for visual selective attention in attention deficit hyperactivity disorder (ADHD). *J Child Psychol Psychiatry* 2005;46(1):94–111. [PubMed: 15660647]
43. Spencer TJ, Biederman J, Madras BK, et al. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. *Biol Psychiatry* 2007;62(9):1059–1061. [PubMed: 17511972]
44. van Dyck CH, Quinlan DM, Cretella LM, et al. Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. *Am J Psychiatry* 2002;159(2):309–312. [PubMed: 11823278]
45. Cortese S, Konofal E, Lecendreux M. Alertness and feeding behaviors in ADHD. *Med Hypotheses* 2008;71(5):770–775. [PubMed: 18678446]
46. Cortese S, Konofal E, Yateman N, Mouroen MC, Lecendreux M. Sleep and alertness in children with attention-deficit/hyperactivity disorder. *Sleep* 2006;29(4):504–511. [PubMed: 16676784]
47. Waring ME, Lapane KL. Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder. *Pediatrics* 2008;122(1):e1–e6. [PubMed: 18595954]
48. King JA, Barkley RA, Barrett S. Attention-deficit hyperactivity disorder and the stress response. *Biol Psychiatry* 1998;44(1):72–74. [PubMed: 9646887]
49. Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain. *Neuropsychopharmacology* 1999;20(1):60–80. [PubMed: 9885786]
50. Agranat-Meged A, Ghanadri Y, Eisenberg I, Ben Neriah Z, Kieselstein-Gross E, Mitrani-Rosenbaum S. Attention deficit hyperactivity disorder in obese melanocortin-4-receptor (*MC4R*) deficient subjects. *Am J Med Genet B Neuropsychiatr Genet* 2008;147B (8):1547–1553. [PubMed: 18777518]
51. Day JJ, Roitman MF, Wightman RM, Carelli RM. Associative learning mediates dynamic shifts in dopamine signaling in the nucleus accumbens. *Nat Neurosci* 2007;10(8):1020–1028. [PubMed: 17603481]
52. Barkley RA. Adolescents with attention-deficit/hyperactivity disorder. *J Psychiatr Pract* 2004;10(1):39–56. [PubMed: 15334986]
53. Volkow ND, Wang GJ, Fowler JS, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. *Am J Psychiatry* 2004;161(7):1173–1180. [PubMed: 15229048]
54. Gjedde A, Wong DF, Rosa-Neto P, Cumming P. Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. *Int Rev Neurobiol* 2005;63:1–20. [PubMed: 15797463]
55. Gatley SJ, Volkow ND, Fowler JS, Dewey SL, Logan J. Sensitivity of striatal [11C]cocaine binding to decreases in synaptic dopamine. *Synapse* 1995;20 (2):137–144. [PubMed: 7570343]
56. Zahniser NR, Doolen S. Chronic and acute regulation of Na<sup>+</sup>/Cl<sup>-</sup>-dependent neurotransmitter transporters. *Pharmacol Ther* 2001;92(1):21–55. [PubMed: 11750035]
57. Winstanley CA, Eagle DM, Robbins TW. Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. *Clin Psychol Rev* 2006;26(4):379–395. [PubMed: 16504359]



**Figure 1. Regions of Interest Used to Extract the D<sub>2</sub>/D<sub>3</sub> Receptor and Dopamine Transporter Measures**


The regions of interest for the midbrain are obtained in several planes, and the shadow is projected to the axial image shown in the figure, which explains why the third ventricle is covered by the region. The x coordinate maps the left-right position; they coordinate, the anterior-posterior position; and the z coordinate, the superior-inferior position.



**Figure 2. Regions in the Brain in Which Dopamine Measures Were Lower in Participants With ADHD Than in Controls**

A, Regions showed significantly lower dopamine D<sub>2</sub>/D<sub>3</sub> receptor availability in participants with attention-deficit/hyperactivity disorder (ADHD) than in controls (obtained from [<sup>11</sup>C]raclopride images). B, Regions showed significantly lower dopamine transporter availability in the participants with ADHD than in controls (obtained from [<sup>11</sup>C]cocaine images).

Significance corresponds to  $P < .005$ , cluster  $> 100$  voxels. The yellow regions identify the areas in the brain for which the measures differed between controls and participants with ADHD. The location of the region that differed was similar for the dopamine D<sub>2</sub>/D<sub>3</sub> receptor and for the dopamine transporter and included the locations of the left ventral striatum (including accumbens and ventral caudate), left midbrain, and left hypothalamus. The z coordinate maps the superior-inferior position.



**Figure 3. Regression Slopes Between Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor and Dopamine Transporter Availability and Scores on Attention**

The Dimension of the Strengths and Weaknesses of Attention-Deficit/Hyperactivity Disorder (ADHD)–symptoms and Normal-behavior (SWAN) rating scale uses a positive scale for symptoms (1 to 3) and a negative scale for the opposite of the symptoms (–1 to –3) ranging from “far below average” to “far above average.” The negative numbers in some of the regions show that the ratio of the specific to nonspecific binding of the radioligand is very low for these regions. The solid line in each scatter plot corresponds to the regression line (line of best fit).

**Table 1**

## Demographic and Clinical Characteristics of Participants

	Controls (n = 44)	ADHD (n = 53)
Age, mean (SD), y	31 (6)	32 (8)
Body mass index	25 (5)	25 (3)
Sex, No. (%)		
Men	30 (68)	27 (51)
Women	14 (32)	26 (49)
Education, mean (SD), y	15 (2)	15 (4)
Smoking status, No. (%)		
Current	1 (2)	4 (7)
Past <sup>a</sup>	4 (9)	1 (2)
CGI-severity, mean (SD)	NA	5 (1)
ADHD subtype, No. (%)	NA	
Inattentive		30 (57)
Hyperactive		4 (7)
Combined		19 (36)
CAARS, mean (SD), score		
Inattention	5 (4)	25 (5)
Hyperactivity	7 (4)	23 (8)
Impulsivity	4 (3)	19 (7)
Self-concept	3 (3)	9 (4)
DSM inattentive	3 (3)	20 (4)
DSM hyperactive	3 (3)	15 (6)
Total symptoms	6 (5)	36 (7)
ADHD index	4 (3)	22 (5)
SWAN, mean (SD), score		
Attention	-1.5 (1)	1.6 (1)
Hyperactivity	-1.2 (1)	0.6 (1)

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CAARS, Conners Adult ADHD Rating Scale; CGI, Clinical Global Impressions Severity; DSM, *Diagnostic and Statistical Manual of Mental Disorders* (Fourth Edition); SWAN, Strengths and Weaknesses of ADHD-symptoms and Normal-behavior.

<sup>a</sup>Two participants had quit smoking in the past year, whereas the others had quit more than 2 years before study start.



**Table 2**

Measures of Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor and Dopamine Transporter Availability<sup>a</sup>

Left Hemisphere	Availability, Mean (SD)		Effect Size <sup>b</sup>	95% Confidence Interval <sup>b</sup>	P Value <sup>c</sup>
	Controls	ADHD			
Dopamine D <sub>2</sub> /D <sub>3</sub> receptor					
Accumbens region	2.85 (0.31)	2.68 (0.28)	0.61	0.06 to 0.30	.004
Caudate	2.80 (0.49)	2.47 (0.61)	0.60	0.10 to 0.56	.005
Midbrain	0.28 (0.14)	0.18 (0.19)	0.57	0.02 to 0.17	.01
Hypothalamic region	0.12 (0.13)	0.04 (0.12)	0.61	0.02 to 0.12	.004
Dopamine transporter					
Accumbens region	0.71 (0.16)	0.63 (0.11)	0.59	0.03 to 0.13	.004
Caudate	0.66 (0.23)	0.53 (0.19)	0.62	0.04 to 0.22	.003
Midbrain	0.16 (0.10)	0.09 (0.11)	0.66	0.03 to 0.12	<.001
Hypothalamic region	-0.01 (0.10)	-0.05 (0.12)	0.36	-0.01 to 0.09	.08

<sup>a</sup>Measures of receptor and transporter availability (BPND=DVR - 1) obtained using an independent region-of-interest analysis to corroborate the statistical parametric mapping findings.

<sup>b</sup>Mean differences and effect sizes for the comparisons between controls and participants with attention-deficit/hyperactivity disorder.

<sup>c</sup>Comparisons correspond to independent samples 2-tailed *t* tests.